These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10850301)

  • 21. Bias reduction in correlation of radiation-absorbed dose with response.
    Koral KF; Zasadny K; Wahl RL
    J Nucl Med; 2004 Jul; 45(7):1271; author reply 1271-2. PubMed ID: 15235076
    [No Abstract]   [Full Text] [Related]  

  • 22. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up.
    Martínez A; Martínez-Ramirez M; Martínez-Caballero D; Beneit P; Clavel J; Figueroa G; Verdú J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(1):13-19. PubMed ID: 27422155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cure of incurable lymphoma.
    DeNardo GL; Sysko VV; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
    J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
    J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Milestones in the development of Lym-1 therapy.
    DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
    Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
    DeNardo SJ; Kroger LA; MacKenzie MR; Mirick GR; Shen S; DeNardo GL
    Cancer Biother Radiopharm; 1998 Feb; 13(1):1-12. PubMed ID: 10850337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
    DeNardo GL; Kukis DL; Shen S; Mausner LF; Meares CF; Srivastava SC; Miers LA; DeNardo SJ
    Clin Cancer Res; 1997 Jan; 3(1):71-9. PubMed ID: 9815540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
    DeNardo G; Yuan A; Goldstein D; Richman C; O'Donnell R; Shen S; Hartmann Siantar C; DeNardo S
    Cancer Biother Radiopharm; 2003 Apr; 18(2):231-7. PubMed ID: 12804049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
    Kukis DL; DeNardo SJ; Mills SL; Shen S; O'Donnell RT; DeNardo GL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):363-9. PubMed ID: 10850321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.
    Kroger LA; DeNardo SJ; DeNardo GL; Xiong CY; Winthrop MD; Gumerlock PH
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3010s-3014s. PubMed ID: 10541336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
    DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
    Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.
    DeNardo GL; Kukis DL; DeNardo SJ; Shen S; Mausner LF; O'Donnell RT; Lamborn KR; Meyers FJ; Srivastava SC; Miers LA
    Cancer; 1997 Dec; 80(12 Suppl):2576-82. PubMed ID: 9406712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
    Salako QA; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1998 Apr; 39(4):667-70. PubMed ID: 9544679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.
    Mirick GR; O'Donnell RT; DeNardo SJ; Shen S; Meares CF; DeNardo GL
    Nucl Med Biol; 1999 Oct; 26(7):841-5. PubMed ID: 10628566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
    Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.